4 research outputs found

    Increasing the Transparency of Animal Experimentation: An Australian Perspective

    Get PDF
    It has been argued that citizen stakeholders would be well served by greater transparency. The Transparency Register of the European Union (eu) (2016), for example, states that “Transparency is […] a key part of encouraging European citizens to participate more actively in the democratic life of the eu”. But why is transparency in non-human animal (hereinafter referred to as animal) research desirable, or indeed vital? Hadley (2012) argues that the public finance much animal research but do not know what impact their taxes and donations have on animals. Furthermore, he suggests that, since “people enjoy the benefits of animal research when they consume pharmaceuticals or undergo surgical procedures that prolong or improve the quality of their lives, it seems reasonable to inform them of the costs to animals for which their consumer choices are to some extent causally responsible” (Hadley, 2012, p. 105). Good governance is another reason for transparency in animal research. Thus, McLeod and Hobson-West suggest that one of the key themes “in the science governance literature is the linking of transparency and public trust (or mistrust)” (2015, p. 792). Varga et al. concur that “more transparency will increase public confidence in the appropriate conduct and regulation of animal research and therefore help to maintain public acceptance” (2010, p. 500)

    Supporting good practice in the provision of services to people with comorbid mental health and alcohol and other drug problems in Australia: describing key elements of good service models

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>The co-occurrence of mental illness and substance use problems (referred to as "comorbidity" in this paper) is common, and is often reported by service providers as the expectation rather than the exception. Despite this, many different treatment service models are being used in the alcohol and other drugs (AOD) and mental health (MH) sectors to treat this complex client group. While there is abundant literature in the area of comorbidity treatment, no agreed overarching framework to describe the range of service delivery models is apparent internationally or at the national level. The aims of the current research were to identify and describe elements of good practice in current service models of treatment of comorbidity in Australia. The focus of the research was on models of service delivery. The research did not aim to measure the client outcomes achieved by individual treatment services, but sought to identify elements of good practice in services.</p> <p>Methods</p> <p>Australian treatment services were identified to take part in the study through a process of expert consultation. The intent was to look for similarities in the delivery models being implemented across a diverse set of services that were perceived to be providing good quality treatment for people with comorbidity problems.</p> <p>Results</p> <p>A survey was designed based on a concept map of service delivery devised from a literature review. Seventeen Australian treatment services participated in the survey, which explored the context in which services operate, inputs such as organisational philosophy and service structure, policies and procedures that guide the way in which treatment is delivered by the service, practices that reflect the way treatment is provided to clients, and client impacts.</p> <p>Conclusions</p> <p>The treatment of people with comorbidity of mental health and substance use disorders presents complex problems that require strong but flexible service models. While the treatment services included in this study reflected the diversity of settings and approaches described in the literature, the research found that they shared a range of common characteristics. These referred to: service linkages; workforce; policies, procedures and practices; and treatment.</p
    corecore